We build disease single cell atlases to explore unchartered cell type specific mechanisms.

We enable deep understanding of the condition through high coverage of different cell types that could be implicated in the disease.

We harness the power of our target discovery engine to first identify cell type specific differential gene expression. Then we use causal approaches on our cell-type specific interactomes to identify driver genes.

Finally, we rank our target list using druggability, safety and novelty criteria, and deliver a target scorecard for strategic decision making.

We leverage our curated drug catalog and network medicine approaches to repurpose drugs with safety profiles targeting our identified driver genes.

We then rank these drugs using safety, and novelty filters associated with business intelligence information to deliver a drug investment scorecard for strategic decision making.

Invivo development timeline depends on the model, disease and drug.

We use drugs that already have FDA approval or validated Phase 1-2 safety profiles, greatly reducing risk and accelerating drug development timelines by delivering candidates poised for clinical success.